Evidence map›Paper›PMID 25971969›Full record

ArticleThe Journal of biological chemistry2015

Functional Genomic Screen Identifies Klebsiella pneumoniae Factors Implicated in Blocking Nuclear Factor κB (NF-κB) Signaling.

Anna Tomás, Leticia Lery, Verónica Regueiro, Camino Pérez-Gutiérrez, Verónica Martínez, David Moranta, Enrique Llobet, Mar González-Nicolau, Jose L Insua, Juan M Tomas and 3 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. O-antigen polysaccharides inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Uncovering the Secretion Systems ofAntibiotics (Basel, Switzerland) · 2023
    Review
  9. Visualisation of Host-Pathogen Communication.Advances in experimental medicine and biology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. HypervirulentMicroorganisms · 2022
    Article
  15. Microorganisms · 2021
    Article
  16. Article
  17. Article
  18. A PorcinemBio · 2019
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 3 countries.

Anna TomásFrom the Infection and Immunity Program, Fundación de Investigación Sanitaria de las Islas Baleares (FISIB), 07110 Mallorca, Spain, the Instituto de Investigación Sanitaria de Palma (IdisPa), 07120 Mallorca, Spain, the Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain.
Leticia Lerythe Unité de Pathogénie Microbienne Moléculaire, Institut Pasteur, 75724 Paris, France, INSERM U786, 75724 Paris, France.
Verónica RegueiroFrom the Infection and Immunity Program, Fundación de Investigación Sanitaria de las Islas Baleares (FISIB), 07110 Mallorca, Spain, the Instituto de Investigación Sanitaria de Palma (IdisPa), 07120 Mallorca, Spain, the Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain.
Camino Pérez-GutiérrezFrom the Infection and Immunity Program, Fundación de Investigación Sanitaria de las Islas Baleares (FISIB), 07110 Mallorca, Spain, the Instituto de Investigación Sanitaria de Palma (IdisPa), 07120 Mallorca, Spain, the Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain.
Verónica MartínezFrom the Infection and Immunity Program, Fundación de Investigación Sanitaria de las Islas Baleares (FISIB), 07110 Mallorca, Spain, the Instituto de Investigación Sanitaria de Palma (IdisPa), 07120 Mallorca, Spain, the Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain.
David MorantaFrom the Infection and Immunity Program, Fundación de Investigación Sanitaria de las Islas Baleares (FISIB), 07110 Mallorca, Spain, the Instituto de Investigación Sanitaria de Palma (IdisPa), 07120 Mallorca, Spain, the Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain.
Enrique LlobetFrom the Infection and Immunity Program, Fundación de Investigación Sanitaria de las Islas Baleares (FISIB), 07110 Mallorca, Spain, the Instituto de Investigación Sanitaria de Palma (IdisPa), 07120 Mallorca, Spain, the Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain.
Mar González-NicolauFrom the Infection and Immunity Program, Fundación de Investigación Sanitaria de las Islas Baleares (FISIB), 07110 Mallorca, Spain, the Instituto de Investigación Sanitaria de Palma (IdisPa), 07120 Mallorca, Spain, the Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain.
Jose L Insuathe Centre for Infection and Immunity, Queen's University Belfast, Belfast BT9 7AE, United Kingdom.
Juan M Tomasthe Departamento de Microbiología, Facultad de Biología, Universidad de Barcelona, 08028 Barcelona, Spain.
Philippe J Sansonettithe Unité de Pathogénie Microbienne Moléculaire, Institut Pasteur, 75724 Paris, France, INSERM U786, 75724 Paris, France, Chaire de Microbiologie et Maladies Infectieuses, Collège de France, 75231 Paris, France.
Régis Tournebizethe Unité de Pathogénie Microbienne Moléculaire, Institut Pasteur, 75724 Paris, France, INSERM U786, 75724 Paris, France, Imagopole, Plateforme d'Imagerie Dynamique, Institut Pasteur, 75724 Paris, France, and.
José A Bengoecheathe Centre for Infection and Immunity, Queen's University Belfast, Belfast BT9 7AE, United Kingdom, the Consejo Superior de Investigaciones Científicas (CSIC), 28008 Madrid, Spain j.bengoechea@qub.ac.uk.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESHealth Research Institute of the Balearic Islands · ESCollège de France · FRConsejo Superior de Investigaciones Científicas · ESFundación Canaria de Investigación Sanitaria · ESInserm · FRInstitut Pasteur · FRQueen's University Belfast · GBUniversitat de Barcelona · ES

Funding

Biotechnology and Biological Sciences Research Council BB/L007223/1
6 · The paper itself

Abstract

Klebsiella pneumoniae is an etiologic agent of community-acquired and nosocomial pneumonia. It has been shown that K. pneumoniae infections are characterized by reduced early inflammatory response. Recently our group has shown that K. pneumoniae dampens the activation of inflammatory responses by antagonizing the activation of the NF-κB canonical pathway. Our results revealed that K. pneumoniae capsule polysaccharide (CPS) was necessary but not sufficient to attenuate inflammation. To identify additional Klebsiella factors required to dampen inflammation, we standardized and applied a high-throughput gain-of-function screen to examine a Klebsiella transposon mutant library. We identified 114 mutants that triggered the activation of NF-κB. Two gene ontology categories accounted for half of the loci identified in the screening: metabolism and transport genes (32% of the mutants) and envelope-related genes (17%). Characterization of the mutants revealed that the lack of the enterobactin siderophore was linked to a reduced CPS expression, which in turn underlined the NF-κB activation induced by the mutant. The lipopolysaccharide (LPS) O-polysaccharide and the pullulanase (PulA) type 2 secretion system (T2SS) are required for full effectiveness of the immune evasion. Importantly, these factors do not play a redundant role. The fact that LPS O-polysaccharide and T2SS mutant-induced responses were dependent on TLR2-TLR4-MyD88 activation suggested that LPS O-polysaccharide and PulA perturbed Toll-like receptor (TLR)-dependent recognition of K. pneumoniae. Finally, we demonstrate that LPS O-polysaccharide and pulA mutants are attenuated in the pneumonia mouse model. We propose that LPS O-polysaccharide and PulA T2SS could be new targets for the design of new antimicrobials. Increasing TLR-governed defense responses might provide also selective alternatives for the management of K. pneumoniae pneumonia.

Indexed as

AnimalsBacterial ProteinsFemaleGenomicsHumansImmune EvasionKlebsiella InfectionsKlebsiella pneumoniaeLipopolysaccharidesMiceNF-kappa BSignal TransductionBacterial ProteinsLipopolysaccharidesNF-kappa BironKlebsiella pneumonialipopolysaccharide (LPS)NF-κ B (NF-κB)pullulanasetoll-like receptor (TLR)

Identifiers

PMID25971969
PMCPMC4505419
OpenAlexW1560126339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.